Gaud, Guillaume http://orcid.org/0000-0001-6066-806X
Achar, Sooraj http://orcid.org/0000-0003-3425-7501
Bourassa, François X. P. http://orcid.org/0000-0002-2757-5870
Davies, John http://orcid.org/0000-0002-9482-1066
Hatzihristidis, Teri
Choi, Seeyoung
Kondo, Taisuke
Gossa, Selamawit
Lee, Jan
Juneau, Paul http://orcid.org/0000-0002-4676-4191
Taylor, Naomi http://orcid.org/0000-0002-2459-4558
Hinrichs, Christian S. http://orcid.org/0000-0001-5597-2841
McGavern, Dorian B. http://orcid.org/0000-0001-9568-545X
François, Paul
Altan-Bonnet, Grégoire http://orcid.org/0000-0002-7283-3162
Love, Paul E. http://orcid.org/0000-0002-6682-7372
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development (HD001803-28)
Article History
Received: 6 October 2022
Accepted: 29 September 2023
First Online: 9 November 2023
Change Date: 6 December 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41590-023-01725-5
Competing interests
: G.G., J.D., C.S.H. and P.E.L. are inventors on an NIH patent using ITAM-mutated CD3ζ to enhance the function of cytotoxic T cells and other immune cells; Patent #: 63/113,428. The remaining authors declare no competing interests.